AR015120A1 - Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica - Google Patents
Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceuticaInfo
- Publication number
- AR015120A1 AR015120A1 ARP980102650A ARP980102650A AR015120A1 AR 015120 A1 AR015120 A1 AR 015120A1 AR P980102650 A ARP980102650 A AR P980102650A AR P980102650 A ARP980102650 A AR P980102650A AR 015120 A1 AR015120 A1 AR 015120A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- amino
- methyl
- tiazolidin
- piridil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmacéutica que comprende 5-[4-(2-(N-metil-N-(2-Piridil) amino)etoxi]bencil]-tiazolidin-2,4-diona [de aqui en adelante compuesto (I)]que la composicion comprende 2 a 12mg de Compuesto (I) en una forma farmacéuticamenteaceptable y opcionalmente un vehículo farmacéuticamenteaceptable para el mismo, un procedimiento para su preparacion y una composicion para la pre-administracion farmacéutica
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015120A1 true AR015120A1 (es) | 2001-04-18 |
Family
ID=26311662
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102649A AR008198A1 (es) | 1997-06-05 | 1998-06-04 | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona |
ARP980102650A AR015120A1 (es) | 1997-06-05 | 1998-06-04 | Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102649A AR008198A1 (es) | 1997-06-05 | 1998-06-04 | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0998284A1 (es) |
JP (1) | JP2001521553A (es) |
KR (1) | KR20010013410A (es) |
CN (3) | CN1526391A (es) |
AP (1) | AP1214A (es) |
AR (2) | AR008198A1 (es) |
AU (1) | AU8215098A (es) |
BG (1) | BG104048A (es) |
BR (1) | BR9810405A (es) |
CA (2) | CA2292629C (es) |
CO (1) | CO4940400A1 (es) |
DZ (1) | DZ2510A1 (es) |
EA (1) | EA002384B1 (es) |
GB (1) | GB9711683D0 (es) |
HU (1) | HUP0004070A3 (es) |
ID (1) | ID24264A (es) |
IL (1) | IL133074A0 (es) |
MX (1) | MXPA99011322A (es) |
NO (2) | NO995938L (es) |
NZ (2) | NZ523725A (es) |
OA (1) | OA11306A (es) |
PE (1) | PE78899A1 (es) |
PL (1) | PL337201A1 (es) |
SK (1) | SK164899A3 (es) |
TR (2) | TR199902963T2 (es) |
TW (1) | TW570797B (es) |
UY (1) | UY25032A1 (es) |
WO (1) | WO1998055122A1 (es) |
ZA (2) | ZA984826B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1903043A1 (en) | 1999-04-23 | 2008-03-26 | SmithKline Beecham P.L.C. | Novel pharmaceutical |
US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
IL146111A0 (en) | 1999-04-23 | 2002-07-25 | Smithkline Beecham Plc | 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt |
GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10199003I1 (de) * | 1987-09-04 | 2003-06-12 | Beecham Group Plc | Substituierte Thiazolidinionderivate |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
CA2182986A1 (en) * | 1994-02-10 | 1995-08-17 | Smithkline Beecham P.L.C. | Use of insulin sensitisers for treating renal diseases |
EA199800177A1 (ru) * | 1995-08-10 | 1998-10-29 | Варнер-Ламберт Компани | Способ снижения количества экзогенного инсулина, вводимого пациенту с инсулиннезависимым сахарным диабетом |
WO1997018811A1 (en) * | 1995-11-17 | 1997-05-29 | Warner-Lambert Company | A method of treating myotonic dystrophy |
NZ314406A (en) * | 1996-03-18 | 2000-12-22 | Sankyo Co | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles |
CN1230114A (zh) * | 1996-07-12 | 1999-09-29 | 史密丝克莱恩比彻姆有限公司 | Leptine抵抗的新疗法 |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Application Discontinuation
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200601145A1 (ru) | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов | |
RS51343B (sr) | Nova kompozicija i njena upotreba | |
AR015120A1 (es) | Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica | |
EA200702648A1 (ru) | Фармацевтическая композиция, пригодная для введения один раз в день | |
AR015894A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
CY1107252T1 (el) | Τρυγικο αλας παραγωγου της θειζολιδινοδιονης | |
NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
ECSP034505A (es) | La sal de clorhidrato de 5-[4-(2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2, 4-diona | |
AR038417A1 (es) | Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral | |
ECSP034469A (es) | Compuesto farmaceutico novedoso | |
DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika | |
BR0112984A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
HRP20010344B1 (en) | Novel method of treatment | |
CY1107421T1 (el) | Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης | |
ECSP034528A (es) | Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona | |
EA200300004A1 (ru) | Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата | |
NZ510672A (en) | Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione | |
ECSP003434A (es) | Nuevos compuestos | |
CO5150180A1 (es) | Nueva composicion y uso liberacion modificada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |